Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis
暂无分享,去创建一个
[1] D. Vidal,et al. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain , 2018, The Journal of dermatological treatment.
[2] D. Ioannides,et al. Secukinumab survival and long‐term efficacy in patients with plaque psoriasis: real‐life data from a tertiary hospital in Greece , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[3] W. Liao,et al. Secukinumab in the treatment of psoriasis: patient selection and perspectives , 2018, Psoriasis.
[4] K. Peris,et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation , 2018, Expert Opinion on Biological Therapy.
[5] M. Augustin,et al. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real‐life data of prior and concomitant use of psoriasis treatments from the PROSPECT study , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[6] L. Skov,et al. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study , 2017, Dermatologic therapy.
[7] S. Chimenti,et al. Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[8] L. Naldi,et al. Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.
[9] A. Kimball,et al. Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy☆☆☆ , 2016, International journal of women's dermatology.
[10] M. Casado,et al. The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review. , 2016, Actas dermo-sifiliograficas.
[11] J. Erickson,et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.
[12] P. Amerio,et al. Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. , 2016, Acta dermato-venereologica.
[13] F. Vanaclocha,et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. , 2015, Journal of the American Academy of Dermatology.
[14] Jashin J. Wu,et al. Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review. , 2015, Journal of the American Academy of Dermatology.
[15] R. Romero-Jimenez,et al. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting. , 2015, Actas dermo-sifiliograficas.
[16] B. Elewski,et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.
[17] S. Feldman. It isn't a perfect world , 2011 .
[18] H. Nakagawa,et al. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study , 2010, The Journal of dermatology.